ACE and colorectal cancer: Genetically proxied ACE inhibition was associated with an increased odds of colorectal cancer (OR equivalent to 1 mm Hg lower SBP: 1.13, 95% CI 1.06 to 1.22; P = 3.6 × 10−4).